DexCom (NASDAQ:DXCM) PT Lowered to $115.00

Posted by on Oct 3rd, 2023

DexCom (NASDAQ:DXCM – Get Free Report) had its target price lowered by equities researchers at Citigroup from $150.00 to $115.00 in a note issued to investors on Monday, FlyOnTheWall reports. Citigroup’s price objective suggests a potential upside of 21.63% from the stock’s previous close.

A number of other analysts have also recently commented on the company. Canaccord Genuity Group upped their price objective on DexCom from $135.00 to $150.00 and gave the company a “buy” rating in a research report on Friday, July 28th. UBS Group lowered their price objective on DexCom from $175.00 to $138.00 and set a “buy” rating for the company in a research note on Wednesday, September 6th. Barclays raised their price target on DexCom from $115.00 to $138.00 and gave the stock an “equal weight” rating in a research note on Monday, July 31st. Oppenheimer raised their price objective on DexCom from $135.00 to $150.00 in a report on Friday, July 28th. Finally, Piper Sandler lifted their price target on DexCom from $150.00 to $160.00 and gave the company an “overweight” rating in a report on Friday, July 28th. Three research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $132.06.

Read Our Latest Report on DexCom

DexCom Price Performance

Shares of DXCM stock opened at $94.55 on Monday. The stock has a market cap of $36.67 billion, a price-to-earnings ratio of 109.94, a PEG ratio of 1.77 and a beta of 1.13. The business’s fifty day moving average is $106.48 and its 200 day moving average is $116.55. DexCom has a twelve month low of $81.06 and a twelve month high of $139.55. The company has a quick ratio of 2.21, a current ratio of 2.42 and a debt-to-equity ratio of 1.16.

DexCom (NASDAQ:DXCM – Get Free Report) last released its earnings results on Thursday, July 27th. The medical device company reported $0.34 EPS for the quarter, topping the consensus estimate of $0.22 by $0.12. The business had revenue of $871.30 million for the quarter, compared to the consensus estimate of $841.16 million. DexCom had a return on equity of 22.01% and a net margin of 11.18%. The company’s revenue for the quarter was up 25.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.17 earnings per share. Research analysts expect that DexCom will post 1.23 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Bridgette P. Heller sold 600 shares of the business’s stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $106.56, for a total value of $63,936.00. Following the completion of the transaction, the director now owns 23,731 shares of the company’s stock, valued at approximately $2,528,775.36. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other DexCom news, Director Steven Robert Pacelli sold 5,031 shares of the business’s stock in a transaction that occurred on Friday, July 14th. The stock was sold at an average price of $136.00, for a total transaction of $684,216.00. Following the completion of the sale, the director now directly owns 126,831 shares in the company, valued at approximately $17,249,016. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Bridgette P. Heller sold 600 shares of the business’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $106.56, for a total value of $63,936.00. Following the sale, the director now owns 23,731 shares of the company’s stock, valued at $2,528,775.36. The disclosure for this sale can be found here. In the last 90 days, insiders sold 10,549 shares of company stock valued at $1,275,573. 0.41% of the stock is owned by company insiders.

Institutional Investors Weigh In On DexCom

A number of large investors have recently made changes to their positions in DXCM. Bank Julius Baer & Co. Ltd Zurich grew its position in shares of DexCom by 141,272.2% in the second quarter. Bank Julius Baer & Co. Ltd Zurich now owns 47,321,524 shares of the medical device company’s stock valued at $6,081,289,000 after purchasing an additional 47,288,051 shares in the last quarter. Norges Bank acquired a new position in DexCom in the fourth quarter valued at approximately $421,378,000. 1832 Asset Management L.P. acquired a new position in DexCom in the fourth quarter valued at approximately $151,538,000. Clearbridge Investments LLC lifted its holdings in DexCom by 304.3% in the first quarter. Clearbridge Investments LLC now owns 1,318,079 shares of the medical device company’s stock valued at $674,329,000 after acquiring an additional 992,049 shares during the last quarter. Finally, Marshall Wace LLP lifted its holdings in DexCom by 2,293.0% in the fourth quarter. Marshall Wace LLP now owns 979,856 shares of the medical device company’s stock valued at $110,959,000 after acquiring an additional 938,909 shares during the last quarter. 93.88% of the stock is currently owned by hedge funds and other institutional investors.

About DexCom

(Get Free Report)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Read More

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.